The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique during both initial implantation and subsequent refill procedures, with ...

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their ...

AI-based screening for pediatric DRD is more cost-effective and increases screening rates compared to traditional ECP methods ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in ...

4D-150 demonstrated safety and efficacy in DME, with no intraocular inflammation and significant visual acuity gains at 3E10 vg/eye. The 3E10 vg/eye dose reduced supplemental injections by 61% ...

The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.